Alexandru Stieber/LinkedIn
Dec 18, 2025, 13:34
Alexandru Stieber Explores VEXAS Syndrome
Alexandru Stieber, Internal Medicine Resident at SUUMC Bucharest, shared on LinkedIn:
”Second set of scientific updates from the SNFMI Congress that took place last week in Tours, France.
The theme of today’s post revolves around VEXAS syndrome, new implications for patients with a VEXAS-like phenotype and the evolving concept of “clonal hematopoiesis of immunological significance” (CHIS).
- proven efficacy of azacitidine treatment in VEXAS patients, even in the absence of myelodysplastic syndrome
- proven pathophysiology of UBA1 mutated myeloid cells that drive an inflammatory millieu which alters normal hematopoiesis
- new links found between clonalhematopoiesis with IDH mutations and inflammatory manifestations (polymyalgia rheumatica and large-vessel vasculitis), with resolution under targeted inhibitors”

Stay updated with Hemostasis Today.
-
Jul 9, 2026, 16:45Rutbaa Ayaz Shaikh: One Step Further in Medical Research
-
Jul 9, 2026, 14:49Celebrating a Century of von Willebrand Disease Research and Care – Seminars in Thrombosis and Hemostasis
-
Jul 9, 2026, 14:38Valance Washington: International Hemostasis Community Prepares for GRC 2026
-
Jul 9, 2026, 14:27Dima Shulkin: Next-Generation AI Models Improve Early Sepsis Recognition
-
Jul 9, 2026, 14:12Omar Hajji: Seasonal Determinants of Mortality in Sepsis and Cardiogenic Shock
-
Jul 9, 2026, 13:54Hussein Yassine: Why Omega-3s May Fall Short in Preventing Alzheimer’s Disease
-
Jul 9, 2026, 13:16Olivier Mathieu: Innovating the Future of Hemostasis at ISTH 2026
-
Jul 9, 2026, 12:41Thomas Palmer-Dench: Hexokinase Controls Platelet Activation and Hemostasis
-
Jul 9, 2026, 12:19Paschalis Evangelidis: Join Our Special Issue on Thrombosis and Vascular Disorders